Objectives The aim of this study was to compare outcomes using two preference-based measures of health status (EQ-5D-5L and OAB-5D) in patients with overactive bladder (OAB) treated with solifenacin plus mirabegron or solifenacin monotherapy in the BESIDE trial. Methods Patients with OAB who remained incontinent after 4 weeks' treatment with solifenacin 5 mg were randomized 1:1:1 to combination treatment (solifenacin 5 mg plus mirabegron [25 mg for the first 4 weeks/50 mg for the last 8 weeks]), solifenacin 5 mg, or solifenacin 10 mg. EQ-5D-5L and OAB-q were administered at baseline, weeks 4, 8, 12, and end of treatment (EoT). OAB-5D scores were derived from OAB-q results. Responder analysis was carried out using several definitions of minimally important difference.
Introduction
Overactive bladder (OAB) is a common and debilitating condition, defined as urinary urgency with/without urgency urinary incontinence, usually with increased daytime frequency and nocturia in the absence of proven infection or other obvious pathology [1] . OAB symptoms compromise health-related quality of life (HRQoL) and negatively affect sleep quality, social activities, self-esteem, relationships, work productivity, physical exercise, psychological health, and sexual activity/enjoyment [2] [3] [4] [5] . Among OAB symptoms, urgency urinary incontinence-present in approximately one-third of OAB cases-has the greatest negative impact on HRQoL and has a major socioeconomic impact [2, 6] .
Mirabegron is a selective b 3 -adrenoreceptor agonist, which relaxes bladder smooth muscle and increases bladder storage capacity [7] . Multiple phase III trials have demonstrated the efficacy and tolerability of this agent in patients with OAB [8] [9] [10] , and mirabegron is indicated for the treatment of urgency, increased micturition frequency, and/or urgency incontinence [11] .
Antimuscarinic agents and mirabegron represent standard of care pharmacological treatment options for OAB. Although the two drug classes provide similar efficacy, mirabegron is not associated with bothersome, typical anticholinergic side effects such as dry mouth [12] . OAB is a chronic condition which often requires long-term management. The occurrence of anticholinergic side effects can potentially limit the use of antimuscarinics in patients for whom symptoms persist [13] . It is therefore of interest to investigate whether the addition of mirabegron, with its different mechanism of action, may improve OAB symptoms, without the need for antimuscarinic dose escalation and potential concomitant increase in anticholinergic burden and adverse effects.
The evaluation of new medical treatments and technologies increasingly involves analysis of their cost effectiveness and cost utility-these analyses form an integral part of health technology assessment (HTA). In many countries, cost-utility analysis (CUA) can also be critical to decision making on reimbursement. Within the CUA framework, preference-based measures (PBMs) of health status provide a multidimensional description of health to which societal preference weights (or utilities) can be attached. These preference weights can then be used in combination with survival data to generate quality-adjusted life-years [14] . One widely used PBM is the EQ-5D, a simple instrument measuring five dimensions of health status, which is the preferred measure of the National Institute for Health and Care Excellence in England/Wales [15] . Although of great value, generic PBMs (e.g., EQ-5D), which are applicable to a wide range of patient groups and conditions, may not capture all aspects of health status relevant to patients with a particular condition. In such cases, condition-specific PBMs are sometimes developed, such as the OAB-5D for patients with OAB [16] . Given that both EQ-5D and OAB-5D could potentially be used to generate utilities for OAB, and given the importance of CUA in HTA and treatment funding discussions, it is critical to understand how the two instruments perform comparatively.
The inclusion of the latest version of EQ-5D (i.e., EQ-5D-5L), which has five response levels for each of the five dimensions [17] , and OAB-5D in a recent phase III trial of OAB (BESIDE [18] ) provided an opportunity for such a comparison within an exploratory analysis presented here. This was the first time that EQ-5D-5L has been compared head-to-head with OAB-5D, and the first time that the new EQ-5D-5L value set for England has been reported in an OAB patient population.
Materials and Methods

Study Design and Patients
BESIDE was a randomized double-blind multicenter phase IIIb trial (NCT01908829) that included multiple investigator sites in Europe, the US, Canada, Australia, and Lebanon; the methods have been published previously [18] . In brief, patients aged C18 years with OAB symptoms for [3 months, including an average of two or more incontinence episodes per 24 h, entered a 2-week screening/washout period to remove the effects of previous OAB medication and to familiarize participants with the patient-recorded electronic micturition diary. Patients then underwent 4-week single-blind treatment with solifenacin 5 mg/day. Patients still experiencing one or more incontinence episodes during a 3-day diary were eligible for randomization (1:1:1) to 12 weeks of combination treatment (solifenacin 5 mg/day plus mirabegron 25 mg/day for 4 weeks then mirabegron 50 mg/day for the remaining 8 weeks), solifenacin 5 mg/day or solifenacin 10 mg/day.
The primary publication reported that the combination significantly reduced daily incontinence episodes (primary endpoint; -1.80 vs -1.53, p \ 0.01), daily micturitions (-1.59 vs -1.14, p \ 0.01) and incontinence episodes over 3 days (4.25 vs 4.87, p = 0.01) compared with solifenacin 5 mg [18] . The combination was non-inferior to solifenacin 10 mg for both key secondary endpoints (daily micturitions [-1.59 vs -1.12, p \ 0.01] and incontinence episodes over 3 days [4.25 vs 4.72, p = 0.13]) and superior to solifenacin 10 mg for daily micturition [18] . In addition, the incidence of dry mouth with the combination was similar to solifenacin 5 mg [18] .
Patient-Reported Outcome Measures
The following patient-reported outcome (PRO) measures were included in the BESIDE trial: the OAB questionnaire (OAB-q), from which OAB-5D preference-based scores can be derived; the patient perception of bladder condition (PPBC) questionnaire; the treatment satisfaction visual analog scale (TS-VAS); the patient and clinician global impression of change (PGIC and CGIC) scales; and the EQ-5D-5L. The analysis in the present paper reports on the EQ-5D-5L, OAB-5D, PGIC and CGIC; outcomes from the PPBC, TS-VAS, and OAB-q are reported separately [19] .
EQ-5D-5L measures health status in five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression [17] . Each dimension has five response levels (1) (2) (3) (4) (5) : no problems, slight/mild problems, moderate problems, severe problems, and extreme problems/unable to perform activity. Respondents are asked to indicate their health status on the day of administration by selecting the most appropriate response for each dimension. The 1-digit numbers for each dimension are then combined to provide a 5-digit descriptive profile of the respondent's overall health state. Societal preference weights generated using trade-off techniques are available in the form of a single index value for each of the 3125 possible EQ-5D-5L health states. In the current analysis, EQ-5D-5L index values were calculated using the recently developed value set for England [20, 21] , with scores which range from -0.281 (worst possible health state, i.e., 55555) to 1 (best possible health state/full health, i.e., 11111).
OAB-5D was derived from OAB-q, a 33-item conditionspecific questionnaire that consists of an eight-item symptom bother scale and a 25-item health status utility measure scale [22] . OAB-5D is a reduced health state classification system that includes five dimensions (urge to urinate, urine loss, sleep impact, coping strategy, and concern with urinary problems) with five severity levels (ranging from 1 denoting no problem to 5 indicating an extreme problem) [16] . Like EQ-5D-5L, OAB-5D generates descriptive profiles representing 3125 unique health states which were translated into a single index value using trade-off techniques in a representative sample of the UK population [23] .
PGIC and CGIC evaluate health status using a simple seven-point single-item scale ranging from 'very much improved' to 'very much worse'. On PGIC, each patient rated any change in his/her bladder symptoms and general health from baseline, whereas CGIC was rated by clinicians based on changes they observed in the patient's bladder symptoms.
Data for the EQ-5D-5L and OAB-5D questionnaires were collected at baseline, at weeks 4, 8, and 12, and end of treatment (EoT); PGIC and CGIC data were collected at EoT only.
Responder Analyses
Responder analyses were performed to determine the number and proportion of patients who achieved at least a minimally important difference (MID), or improvement, on EQ-5D-5L or OAB-5D. The MID can be defined as the smallest change that is perceived by patients as beneficial or that would result in a change in treatment [24] . However, there are multiple ways of estimating an MID and they usually give a range of possible values. There are no previously published MID values for EQ-5D-5L or OAB-5D, and we used several approaches to estimating them for the present study. As there is no agreement on which method for estimating MIDs is the most appropriate for health status utility measures such as those used here, we performed several responder analyses using the different MIDs derived for the current analysis. For EQ-5D-5L, a responder was defined by an incremental improvement from baseline to EoT of at least (a) 0.017 (i.e., the mean increment in patients who reported at least minimally improved health on the PGIC); (b) 0.102 (i.e., 0.5 standard deviation [SD] of the mean index value for the total study population at baseline); and (c) 0.065 (i.e., mean change in utility associated with a one-level change in any dimension of the descriptive system; e.g., 11112 vs 11113) estimated as described in Luo et al. [25] . The same approaches were applied to OAB-5D, generating MIDs of (a) 0.054; (b) 0.043; and (c) 0.020, respectively. In addition, double responder analyses were conducted for EQ-5D-5L and OAB-5D by combining the data for two definitions of MID described above; that is, assessing the proportion of patients who achieved two MIDs (e.g., EQ-5D-5L C 0.017 and OAB-5D C 0.054).
Statistical Analyses
EQ-5D-5L and OAB-5D data were analyzed using a modified full analysis set (mFAS), defined as all randomized patients [after 4-week solifenacin run-in] who received one or more doses of double-blind treatment, had eight or more micturitions per 24 hours at and after baseline, had one or more incontinence episode per 24 hours at baseline, and completed the EQ-5D-5L questionnaire at baseline and at least once postbaseline. Patients with missing baseline EQ-5D-5L values were excluded; missing values at EoT were imputed using last observation carried forward. Analyses were also performed using a per-protocol set (PPS), which included all patients in the mFAS except those meeting additional exclusion criteria (Supplementary Table 1 , see Electronic Supplementary Material [ESM]). Categorical variables were summarized by counts and percentages and compared between treatments by Chi-square tests, while mean (SD) and Student's t tests were used for continuous variables. Analysis of covariance (ANCOVA) models were used to compare changes in EQ-5D-5L and OAB-5D index scores from baseline to EoT, adjusting for the following covariates: baseline index score, sex, age, geographic region, and 4-week incontinence reduction (yes/ no). Spearman's correlation estimate analyses were performed between the PGIC and CGIC data and the EQ-5D-5L and OAB-5D index data.
Results
The mFAS included 2054 patients (combination, n = 694; solifenacin 5 mg, n = 684; solifenacin 10 mg, n = 676). Overall, 1902 patients comprised the PPS (combination, n = 631; solifenacin 5 mg, n = 640; solifenacin 10 mg, n = 631). Similar baseline demographic and clinical characteristics were observed across the three treatment arms in the mFAS (Table 1 ) and PPS.
EQ-5D-5L and OAB-5D indices
The mean change with EQ-5D-5L index from baseline to EoT was statistically significant for combination therapy (0.059; adjusted p \ 0.01), solifenacin 5 mg (0.040; adjusted p \ 0.01), and solifenacin 10 mg (0.044; adjusted p \ 0.01) (Fig. 1a) ; the magnitude of change was not statistically significant for combination therapy versus solifenacin 5 mg (adjusted p = 0.12) and solifenacin 10 mg (adjusted p = 0.11). The proportion of patients with EQ-5D-5L scores indicating full health/no problems on any dimension (i.e., 11111 profile) increased at EoT (43-47%) versus baseline (29-30%) and was similar across the three treatment arms (Supplementary Table 2, see ESM) .
Using OAB-5D, the improvement in health status from baseline to EoT was significantly greater with the combination (0.107; adjusted p \ 0.01), solifenacin 5 mg (0.085; adjusted p \ 0.01), and solifenacin 10 mg (0.087; adjusted p \ 0.01) (Fig. 1b) , and with the combination versus solifenacin 5 mg (adjusted p \ 0.01) and solifenacin 10 mg (adjusted p \ 0.01). The proportion of patients with OAB-5D scores reporting full health was greater at EoT (9-13%) versus baseline (0-1%) and was similar at both time points across the three treatment arms (Supplementary  Table 2 , see ESM). The dimension score results based on the PPS were similar to mFAS (data not shown).
Questionnaire Dimensions: EQ-5D-5L
and OAB-5D
The EQ-5D-5L dimensions showing most improvement in terms of the proportion of patients who switched from FAS (randomized patients [after 4-week solifenacin run-in] who received C1 dose of study treatment and completed the EQ-5D-5L questionnaire at baseline and at least once post-baseline), mFAS modified full analysis set, OAB overactive bladder, SD standard deviation reporting problems at baseline to 'no problems' at EoT were anxiety/depression, pain/discomfort, and usual activities. This finding was common to all three treatment arms (Fig. 2a) . The proportion of patients reporting no problems in OAB-5D dimensions also increased from baseline to EoT in all three treatment arms (Fig. 2b) ; the largest improvements were observed for the combination treatment and were seen on the urge (3 to 24%), urine loss (3 to 42%), and coping (8 to 36%) dimensions. 52.0%, p = 0.01) and CGIC bladder symptoms (very much/much improved: 74.1 vs 64.8%, p \ 0.01; and 69.0%, p = 0.03) with combination, solifenacin 5 mg, and solifenacin 10 mg, respectively.
PGIC and CGIC
Responder Analyses
With EQ-5D-5L, no statistically significant differences in responder rates, according to all definitions of MID, were observed between any treatment arms ( Table 2 ). In contrast, the combination group showed higher responder rates than solifenacin monotherapy according to all definitions of MID using OAB-5D (Table 2) ; no significant differences were observed between solifenacin 5 mg and 10 mg.
In the double responder analysis, the proportion of responders was significantly greater with the combination compared with both solifenacin arms using the EQ-5D-5L MID C0.017 and the OAB-5D MIDs C0.054 and C0.043 (all p B 0.05; Table 2 ). The proportion of responders for other combinations of MID definitions was numerically greater for the combination compared with solifenacin monotherapies, but the differences were not statistically significant.
Correlation of EQ-5D-5L and OAB-5D with PGIC and CGIC
In patients who reported very much/much improvement in PGIC bladder, the change in mean EQ-5D-5L index scores was numerically greater in the combination group compared with solifenacin 5 and 10 mg (0.072 vs 0.064 and 0.058, respectively). Similar changes in EQ-5D-5L index scores for combination versus monotherapy were observed in patients with very much/much improved PGIC general health (0.082 vs 0.067 and 0.068, respectively) and very much/much improved CGIC bladder (0.071 vs 0.062 and 0.052, respectively) (Supplementary Table 4 Table 5 , see ESM). The Spearman's analysis showed a positive correlation (p \ 0.01) between ratings on PGIC and EQ-5D-5L and OAB-5D (Supplementary Table 6 , see ESM).
Discussion
Consistent with earlier observations of significantly improved HRQoL via OAB-q, PPBC, and TS-VAS in BESIDE [19] , the present analysis shows that benefits were observed in the combination and solifenacin monotherapy arms at EoT compared with baseline using both the generic and condition-specific measures. These results complement the earlier published findings from the BESIDE trial which showed that the combination of solifenacin 5 mg plus mirabegron significantly improves symptoms of OAB compared with solifenacin monotherapy in incontinent OAB patients [18] . Most notably, the combination was superior to solifenacin 5 mg alone in improving symptoms of incontinence among patients who remained incontinent despite initial solifenacin 5 mg treatment [18] . Table 2 Responder analysis for EQ-5D-5L and OAB-5D at EoT in the mFAS The EQ-5D-5L Index and individual EQ-5D-5L dimensions showed no significant differences in the degree of change between study arms. A lack of significant difference between study arms on EQ-5D-3L (i.e., five dimensions with three levels) was also observed in a pooled analysis of three phase III studies of mirabegron [26] . However, the magnitude of change in EQ-5D-5L Index scores (from baseline to week 12) in this earlier study (0.026-0.045) was similar to that observed in the present study (0.040-0.059). The fact that EQ-5D-5L is a generic instrument that measures core dimensions of health status, which need to be relevant to a wide range of patient groups with differing severity/number of symptoms, may make it less sensitive to the type of between-arm differences observed in this OAB patient group. The high ceiling effect (29-30% of patients reported full health at baseline) may have also reduced the instrument's ability to distinguish between groups or to fully capture changes over time.
In contrast, the condition-specific OAB-5D index was more sensitive to changes in health status than EQ-5D-5L and showed statistically significant differences between treatment arms. These findings are consistent with an earlier report of health-state utilities for patients with OAB, which evaluated both measures in a pooled analysis of three large, multicenter, placebo-controlled trials [27] . That the OAB-5D index is more sensitive than EQ-5D-5L for detecting changes in health status is not unexpected, as condition-specific instruments include items of more relevance to a particular condition and are likely to be less influenced by natural variation in health status unrelated to the specific condition.
Among OAB symptoms, urgency urinary incontinence is recognized as having the greatest negative impact on HRQoL [3] . The most notable improvements observed on OAB-5D in the present study were observed in the urge, urine loss, and coping dimensions-this likely reflects the significant improvements in incontinence and micturition symptoms observed with the combination [18] . Together, the data are in consonance with the results from recent discrete choice experiments that showed patients with OAB have a preference for avoidance of urgency and incontinence episodes and reduction in micturition frequency [28, 29] , and suggest that improvements captured by OAB-5D in the current study occurred to important dimensions that are likely of particular relevance to patients with OAB.
During the BESIDE trial, the combination treatment was well tolerated. In particular, the incidence of dry mouthwhich is frequently reported with antimuscarinics and a common reason for treatment discontinuation-was lower with combination versus solifenacin 10 mg and similar to solifenacin 5 mg [16] . A treatment which maintains efficacy while constraining side effects is likely to show a greater advantage in terms of utility. Although we did not directly analyse the impact of dry mouth and other side effects in the present study, a recent publication showed that the side effects of antimuscarinic treatment (mainly dry mouth, but also constipation) can have a considerable negative impact on EQ-5D utilities [30] .
For the combination treatment, the change in EQ-5D-5L scores from baseline to EoT (0.06) exceeded the threshold value for one of the three MIDs (i.e., 0.017 based on PGIC) and was approximately the same value as the MID calculated using the one-step transition methodology (i.e., 0.065), suggesting that the change observed on EQ-5D was meaningful [25] . While there were no statistically significant differences in the proportion of responders between the three treatment arms using EQ-5D-5L, the differences between arms were significant using OAB-5D, with the combination arm reporting the highest rate of responders. Furthermore, on OAB-5D, baseline to EoT changes in OAB-5D scores for all three treatments exceeded all the MIDs used.
Study strengths include the fact that the data are derived from a large randomized, controlled, phase III trial and the use of well defined health status utility measures. This is the first time MIDs have been calculated with the EQ-5D-5L value set for England or with OAB-5D, though further studies are required to confirm these values. It should also be noted that these MIDs are specific to the value sets used to estimate utilities in the present study and they may not be transferable to other value sets or other patient populations. Further studies should also assess the impact of combination treatment on HRQoL in males, who were underrepresented in BESIDE, and to assess the impact of mirabegron with/without solifenacin on HRQoL in routine clinical practice.
Conclusions
In this analysis of data from the BESIDE trial, both preference-based health status measures analyzed showed improvements from baseline to EoT in all three treatment arms. However, only the condition-specific measure showed a statistically significant benefit for combination treatment versus solifenacin monotherapy.
Using the more sensitive condition-specific OAB-5D instrument in combination with EQ-5D-5L makes it possible to evaluate the impact of treatment on dimensions of health status that are important to patients with OAB, while also permitting comparisons of outcomes from this study with different disease areas, in which EQ-5D-5L is used, that might be important for HTA decision making. From a clinical perspective, use of combination treatment appears to be justified by gains in condition-specific HRQoL over and above those achieved with monotherapy.
